ArticleArthritis & rheumatology (Hoboken, N.J.)2023

Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab.

Jun Won Park et al.PubMed ↗Publisher ↗

No numbers read from the abstract.